MINI FUTURE LONG - ZEALAND PHARMA Stock

DE000ME4D4D0

Real-time Bid/Ask 10:23:08 2024-06-06 am EDT
5 ^EUR / 5.05 ^EUR	+13.18%

Current month	-8.07%
1 month	-3.27%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ZEALAND PHARMA A/S

Latest news about ZEALAND PHARMA A/S

Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL	06:30am	GL
Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL	06:29am	CI
Zealand Pharma Secures EU Panel Backing for Severe Hypoglycemia Treatment	May. 31	MT
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency	May. 31	GL

More news

Quotes 5-day view

Date	Price	Change
24-06-06	5.06	+13.96%
24-06-05	4.44	-0.22%
24-06-04	4.45	-9.74%
24-06-03	4.93	+2.07%
24-05-31	4.83	+10.78%

Delayed Quote Börse Stuttgart

Last update June 06, 2024 at 08:24 am EDT

More quotes

Static data

Product type	Knock-Out mit Stop Loss
Buy / Sell	CALL
Underlying	ZEALAND PHARMA A/S
Issuer	Morgan Stanley
WKN	ME4D4D
ISIN	DE000ME4D4D0
Date issued	2023-11-29
Strike	277.4 kr
Maturity	Unlimited
Parity	10 : 1
Emission price	0.75 €
Emission volume	N/A
Settlement	Barausgleich
Currency	EUR

Technical Indicators

Highest since issue	6.57 €
Lowest since issue	0.71 €
Spread	0.05 €
Spread %	0.99%

Company Profile

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.

Sector

More about the company

Ratings for Zealand Pharma A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Zealand Pharma A/S

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

610.5 DKK

Average target price

785.6 DKK

Spread / Average Target

+28.68%

Consensus